Aspire BioPharma is trading at $8.89, up 5.71%, with biotech-sector sentiment a possible backdrop.
- No company-specific announcement explaining the October 20 move surfaced in the search; the latest listed company press release was dated September 2026.
- Merck agreed to acquire Silence Therapeutics in a deal reported October 19; this is sector context, not a direct Aspire BioPharma catalyst.